Marshall Wace’s aTyr Pharma ATYR Stock Holding History

Marshall Wace’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Buy	368,120 +230,002	+167%	+$150K	﹤0.01%	2807
2026 Q1	$108K	Buy	+138,118	New	+$117K	﹤0.01%	2883
2025 Q3	–	Sell	-511,412	Closed	-$2.59M	–	3510
2025 Q2	$2.59M	Sell	511,412 -327,040	-39%	-$1.29M	﹤0.01%	1452
2025 Q1	$2.53M	Buy	+838,452	New	+$3.06M	﹤0.01%	1366
2024 Q4	–	Sell	-14,031	Closed	-$24.7K	–	3084
2024 Q3	$24.7K	Buy	+14,031	New	+$25.5K	﹤0.01%	2426
2024 Q2	–	Sell	-158,619	Closed	-$309K	–	3053
2024 Q1	$309K	Buy	+158,619	New	+$277K	﹤0.01%	2098
2023 Q2	–	Sell	-10,947	Closed	-$23K	–	3047
2023 Q1	$23K	Sell	10,947 -129,349	-92%	-$283K	﹤0.01%	2569
2022 Q4	$307K	Sell	140,296 -35,614	-20%	-$84K	﹤0.01%	2561
2022 Q3	$527K	Buy	175,910 +16,503	+10%	+$55.3K	﹤0.01%	2699
2022 Q2	$450K	Sell	159,407 -43,600	-21%	-$158K	﹤0.01%	2837
2022 Q1	$1.09M	Sell	203,007 -47,389	-19%	-$269K	﹤0.01%	2417
2021 Q4	$1.87M	Buy	250,396 +207,390	+482%	+$1.73M	﹤0.01%	2081
2021 Q3	$390K	Buy	+43,006	New	+$257K	﹤0.01%	2520

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's ATYR Position: Q2 2026 in Review

Marshall Wace increased its aTyr Pharma (ATYR) stake by 167% in Q2 2026, buying an estimated $150K and bringing the position to 368,120 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.

Marshall Wace first reported a position in ATYR in Q3 2021 and has held it in 13 quarters since. The position peaked at $2.59M in Q2 2025. 89 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Marshall Wace held 368,120 shares of aTyr Pharma worth $221K as of Q2 2026.
Marshall Wace bought 230,002 aTyr Pharma shares in Q2 2026, an estimated $150K.
aTyr Pharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2807 holding.
Marshall Wace first reported a position in aTyr Pharma in Q3 2021 and has held it in 13 quarters since.
Marshall Wace's aTyr Pharma position peaked at $2.59M in Q2 2025.
89 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.